SINGAPORE – The days of blockbuster drugs may be coming to an end, but Harish Dave, chief medical officer at Singapore-based Aum Biosciences Pte. Ltd., offered companies a new term. During the second day of the Phar-East Pharma and Biotech Festival biopharma conference, Dave said companies should focus on "niche-busters" and finding new sectors to dominate instead.
SINGAPORE – Several talks and forums at the recent Phar-East Pharma and Biotech Festival focused on funding and its relation to the ecosystem in Asia. Naturally, much of this discussion centered on Singapore, the host country for the event and the most developed biotech and med-tech hub in Southeast Asia. Tong Hsien-Hui, head of venture investing at SGInnovate, said it makes sense for Singapore, given its size, to build its ecosystem to focus on niches.
HONG KONG – Legochem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a research collaboration and license agreement to develop antibody-drug conjugates (ADCs) in immuno-oncology, a follow-up to their deal in 2017 to evaluate the potential of next-generation ADC candidates based on Legochem's ADC linker and conjugation technology platform, Conjuall. (See BioWorld, Jan. 25, 2017.)
HONG KONG – Legochem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. have entered into a research collaboration and license agreement to develop antibody-drug conjugates (ADCs) in immuno-oncology, a follow-up to their deal in 2017 to evaluate the potential of next-generation ADC candidates based on Legochem's ADC linker and conjugation technology platform, Conjuall.
SINGAPORE – Several talks and forums at the recent Phar-East Pharma and Biotech Festival focused on funding and its relation to the ecosystem in Asia. Naturally, much of this discussion centered on Singapore, the host country for the event and the most developed biotech and med-tech hub in Southeast Asia. Tong Hsien-Hui, head of venture investing at SGInnovate, said it makes sense for Singapore, given its size, to build its ecosystem to focus on niches.
SINGAPORE – The days of blockbuster drugs may be coming to an end, but Harish Dave, chief medical officer at Singapore-based Aum Biosciences Pte. Ltd., offered companies a new term. During the second day of the Phar-East Pharma and Biotech Festival biopharma conference, Dave said companies should focus on "niche-busters" and finding new sectors to dominate instead.
SINGAPORE – For David Lane, chief scientist at the Agency for Science, Technology and Research (A*STAR), it is clear what is required for driving innovation in Asia.
SINGAPORE – For David Lane, chief scientist at the Agency for Science, Technology and Research (A*STAR), it is clear what is required for driving innovation in Asia. "You need to sustain basic science," Lane said in his opening keynote speech at the Phar-East Pharma and Biotech Festival on Tuesday. "People want instant results, but sustaining basic science is the key to innovation."
